PIK3CA and breast carcinoma: Recent work from Rosen and colleagues revealed that PI3K inhibition in breast cancer cells harboring oncogenic PI3K mutations induces a transient decrease in RAS–MAPK signaling, which could be blunted by expression of exogenous mutant RAS32.